1 / 27

Recent Advances in Antiretroviral Therapy

Recent Advances in Antiretroviral Therapy. Hail M. Al-Abdely, MD Consultant, Infectious Diseases. Rationale for Drug Combinations. CD4 + cell. NRTIs Work here. NNRTIs Work here. PIs Work here. Development of AIDS is like an impending train wreck Viral Load = Speed of the train

jed
Download Presentation

Recent Advances in Antiretroviral Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Recent Advances in Antiretroviral Therapy Hail M. Al-Abdely, MD Consultant, Infectious Diseases

  2. Rationale for Drug Combinations CD4 + cell NRTIs Work here NNRTIs Work here PIs Work here

  3. Development of AIDS is like an impending train wreck Viral Load = Speed of the train CD4 count = Distance from cliff HIV infection J. Coffin, XI International Conf. on AIDS, Vancouver, 1996

  4. Viral Dynamics of HIV-1 Infection Latently infected CD4 lymphocytes Productively infected CD4 lymphocytes <1% T 1/2 ~1.6d 99% Uninfected CD4 lymphocytes 2.6 days per generation T1/2 ~5.7 hrs HIV CD4 lymphocytes infected with defective virus <1% Uninfected activated CD4 lymphocytes Long-lived cell populations Perelson et.al. Science 271:1582 (1996)

  5. Viral dynamics • it takes 2.6 days to produce a new generation of viral particles • estimated total HIV production is 10.3 x 109 virions per day • at least 99% of the virus pool is produced by recently infected cells • retroviral therapy should be able to reduce viral load within a few days

  6. GOALS OF THERAPY • Clinical goals:Prolongation of life and improved quality of life • Virologic goals: Reduction in viral load as much as possible for as long as possible to: 1) halt disease progression, and 2) prevent/reduce resistant variants • Immunologic goals:Achieve immune reconstitution that is quantitative (CD4 to normal range) and qualitative (pathogen-specific immune response) • Therapeutic goals:Rational sequencing of drugs in a fashion that achieves virologic goals, but also: 1) maintains therapeutic options; 2) is relatively free of side effects; and 3) is realistic in terms of probability of adherence • Epidemiologic goals:Reduce HIV transmission

  7. Antiretroviral Drugs Approved by FDA for HIV Generic Name Class Firm FDA Approval Date zidovudine, AZT NRTI Glaxo Wellcome March 87 didanosine, ddI NRTI Bristol Myers-Squibb October 91 zalcitabine, ddC NRTI Hoffman-La Roche June 92 stavudine, d4T NRTI Bristol Myers-Squibb June 94 lamivudine, 3TC NRTI Glaxo Wellcome November 95 saquinavir, SQV, hgc PI Hoffman-La Roche December 95 ritonavir, RTV PI Abbott Laboratories March 96 indinavir, IDV PI Merck & Co., Inc. March 96 nevirapine, NVP NNRTI Boehringer Ingelheim June 96 nelfinavir, NFV PI Agouron Pharmaceuticals March 97 delavirdine, DLV NNRTI Pharmacia & Upjohn April 97 zidovudine and lamivudine NRTI Glaxo Wellcome September 97 saquinavir, SQV, sgc PI Hoffman-La Roche November 97 efavirenz, EFV NNRTI DuPont Pharmaceuticals September 98 abacavir, ABC NRTI Glaxo Wellcome February 99 amprenavir PI Glaxo Wellcome April 99

  8. Trends in Age-Adjusted* Rates of Death due to HIV Infection, USA, 1982-1998 *Using the age distribution of the projected year 2000 US population as the standard. **Preliminary 1998 data

  9. Good News Highly active antiretroviral therapy has Changed our view toward HIV from inevitably fatal to a manageable disease over several decades

  10. Bad News • Incomplete response • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  11. Bad News • Incomplete response • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  12. Bad News • Incomplete response • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  13. Bad News • Incomplete response • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  14. Bad News • Incomplete response • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  15. Bad News • Incomplete response • Complete RNA suppression and sustained CD4 increase happens only in 60-80%. • Effectiveness is even lower in patients with high replication rates and extensive antiretroviral experience. • Complexity of treatment • Short and long term side effects • Cross resistance • Drug-drug interactions

  16. Immunotherapy

  17. Immunotherapy • Directions • Augmentation of specific immune response to control viral replication. • Preventive Vaccines.

  18. Clues to immune control of HIV? Subject JP: Sx: Fever, Rash, Headache Dx: HIV ELISA Neg. HIV RNA >700,000 F/U: Extensive Rx AIDS at 11 mo. Rapid CD4 cell decline Viral Load >750,000 Subject 161J: Sx: Fever, Rash, Headache Dx: HIV ELISA Neg. HIV ELISA Pos. F/U: No Rx Well at 19 yrs. CD4 1000 Viral Load < 500

  19. Acute HIV-1 infection Stimulation of HIV-1-specific immune CD4 cells (Helper cells) Generation of HIV-1-specific killer cells (CTL) Infection of activated helper cells Loss of CTL function due to inadequate HIV-1-specific helper cells Loss of HIV-1-specific helper cells Progression

  20. T helper cells are the central orchestrator of the immune system CTL Function NK Cell Function T helper cell B Cell Function APC Function Antibody Production Cytokine production

  21. Acute HIV-1 infection Stimulation of HIV-1-specific immune CD4 cells (Helper cells) Antiviral Rx Generation of HIV-1-specific killer cells (CTL) Protection of activated helper cells Maintenance of CTL function due to adequate HIV-1-specific helper cells Maintenance of HIV-1-specific helper cells Nonprogression

  22. 0 Months 2 Months HIV-1-specific T helper cells in individuals treated during acute infection (n=7) 1 0 0 1 0 1 M B J C K M N D S J D K K S

  23. Barriers to the Development of an Effective AIDS Vaccine • Sequence variation • Protective immunity in natural infection not clearly established • Desire to achieve sterilizing immunity • Lack of adequate animal model to study vaccine protection with HIV • Latency and integration of HIV into host genome • Transmission by cell-associated virus • Limited knowledge about mucosal transmission and immune responses • Financial disincentives • Ethical issues

More Related